Paul Berg’s Post

🔔Have a look to this scientific session🔔: TRL IS COSTLY: THE VALUE OF ELUVIA DES AN ENDOVASCULAR APPROACH IN FEM-POP DISEASE With unrestricted support of Boston Scientific #toracicaorta #abdominalaorta #peripheralarterialdisease #endoavf #dialysisistula #criticalallimbischemia #abdominalaorta

Natural history studies can support approvals of new rare disease therapies. If you integrate these real-world, protocol-driven studies into the early clinical development planning process, there will be a host of benefits: https://bit.ly/3VYvmJr #raredisease #realworldstudies

INSIDE LOOK 👀 Read more of the latest research from the upcoming issue (September 9): Is the achievement of sputum culture conversion in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) and cavitary lesions associated with the prognosis? Read the full original research in the September issue to learn more: https://hubs.ly/Q02NR5wG0 #MedEd #JournalCHEST

Traditional real-world data, such as data from claims and EHRs, misses a big part of your patients’ stories. Join experts from Evidation and rheumission to hear case studies and best practices for filling important blanks, specifically in autoimmune disease: https://gag.gl/IZTIEm #webinar #autoimmunedisease #autoimmune #RWD #RWE

Traditional real-world data, such as data from claims and EHRs, misses a big part of your patients’ stories. Join experts from Evidation and rheumission to hear case studies and best practices for filling important blanks, specifically in autoimmune disease: https://gag.gl/IZTIEm #webinar #autoimmunedisease #autoimmune #RWD #RWE

Parkinson’s disease (PD) heterogeneity poses many challenges. Learn more about the evidence for and against a-synuclein's role in PD pathogenesis, as well as the current proposals to biologically define and classify PD. #MDSCongress mdscongress.org

We are quickly approaching the ANRF Annual Research Scholar Symposium on March 16th, celebrating the latest discoveries in #arthritis and #autoimmune disease research. Join us! https://ow.ly/fExG50QGiiW #ANRFSymposium #CureArthritis

Natural history studies can support approvals of new rare disease therapies. If you integrate these real-world, protocol-driven studies into the early clinical development planning process, there will be a host of benefits: https://bit.ly/4cwtkas #raredisease #clinicalstudies

Standard of Care can oftentimes be the biggest competitor when it comes to country and site selection. This case study with Bioncle Emas highlights how #TrialHub’s Standard of Care module helped identify the right countries and sites for a Phase 4 rare disease study, and with our real-time insights at their fingertips, they were able to accomplish this 50% faster! Feasibility research is hard, we can help. #feasibility #raredisease #standardofcare https://lnkd.in/grkthsTZ

Here is how decentralized clinical trials (DCTs) can enhance rare disease research in three key ways.